Keytruda Approved for Treatment of Stage III Melanoma

The US Food and Drug Administration FDA has approved Keytruda for the adjuvant treatment of patients with melanoma with involvement of lymph nodes following complete surgical resection Adjuvant Therapy in Melanoma Melanoma is separated into five staging c [...]

Keytruda Plus Inlyta Improves Survival Compared ot Sutent for Treatment of Advanced Kidney Cancer

Results from the randomized phase III KEYNOTE-426 clinical trial show that first-line therapy with a combination of the PD-1 targeted immunotherapy Keytruda pembrolizumab and the VEGF-targeted tyrosine kinase inhibitor Inlyta axitinib improved overall sur [...]

FDA Approves Nivolumab and Ipilimumab Combination for Advanced Kidney Cancer

The Food and Drug Administration FDA approved the immunotherapy drugs Opdivo and Yervoy in combination as an initial or first-line treatment for patients with advanced kidney cancer whose disease has an intermediate or poor prognosis This is the first imm [...]

Adjuvant Taxotere Doesn’t Improve Outcomes in Early Stage High Risk Prostate Cancer

Patients with high-risk non-metastatic prostate cancer saw no survival advantage and no delay in metastases with the addition of adjuvant docetaxel to androgen deprivation therapy ADT according to the results of a pivotal clinical randomized trial publish [...]

Personalized Vaccine to be Tested in Patients with Kidney Cancer

By pairing a novel personalized cancer vaccine with a more established immunotherapy drug that is administered to patients in an innovative fashion scientists at Dana-Farber Cancer Institute are testing a first-of-its-kind strategy aimed at improving outc [...]

TVEC-Genetically Modified Virus Injection into Tumor – A Valid Treatment for Metastatic Melanoma

Results published in the Journal of the American College of Surgeons show sustained effectiveness of disease response and favorable side effect profile CHICAGO January 25 2019 Injection of a genetically modified virus that induces the bodys own immune cel [...]